Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Targeted Oncology offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Editor-in-chief
  • Martin Chopra
Publishing model
Hybrid. Open Choice – What is this?
Impact
Impact factor: 3.683 (2018)
Five year impact factor: 3.118 (2018)
Speed
Submission to first decision: 26 days
Acceptance to publication: 22 days
Usage
Downloads: 74,351 (2018)

Articles

About this journal

Electronic ISSN
1776-260X
Print ISSN
1776-2596
Abstracted and indexed in
  1. EBSCO Biomedical Reference Collection
  2. EBSCO CINAHL
  3. EBSCO Discovery Service
  4. EMBASE
  5. Gale
  6. Gale Academic OneFile
  7. Gale InfoTrac
  8. Google Scholar
  9. INIS Atomindex
  10. Institute of Scientific and Technical Information of China
  11. Japanese Science and Technology Agency (JST)
  12. Journal Citation Reports/Science Edition
  13. Medline
  14. Naver
  15. OCLC WorldCat Discovery Service
  16. ProQuest Central
  17. ProQuest Consumer Health
  18. ProQuest Health & Medical Collection
  19. ProQuest Health Research Premium Collection
  20. ProQuest Medical Database
  21. ProQuest Nursing & Allied Health Database
  22. ProQuest Pharma Collection
  23. ProQuest-ExLibris Primo
  24. ProQuest-ExLibris Summon
  25. Reaxys
  26. SCImago
  27. SCOPUS
  28. Science Citation Index Expanded (SciSearch)
  29. Semantic Scholar
Copyright information

Rights and permissions

Springer Nature policies

© Springer Nature Switzerland AG